Kin Yee, MD
Ophthalmology · Sacramento, CANPI 1205035144
Payments from drug & device makers
Across 61 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$500
- Genentech USA, Inc.$387
- Regeneron Healthcare Solutions, Inc.$318
- Astellas Pharma US Inc$208
- Mallinckrodt Hospital Products Inc.$170
- Genentech, Inc.$121
- plus $379 from 9 others
What the payments were for
- Food & beverage$2,082100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 10 | $500 |
| Genentech USA, Inc. | 11 | $387 |
| Regeneron Healthcare Solutions, Inc. | 10 | $318 |
| Astellas Pharma US Inc | 8 | $208 |
| Mallinckrodt Hospital Products Inc. | 7 | $170 |
| Genentech, Inc. | 1 | $121 |
| Bausch & Lomb Americas Inc. | 1 | $108 |
| AbbVie(2 entities) | 3 | $58 |
| Biogen | 2 | $45 |
| Ocular Therapeutix, Inc. | 2 | $41 |
| Amgen | 2 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Alimera Sciences, Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,082 in reported general payments places this provider in the 55th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 180 | $7,692 |
| Ketorolac Tromethamine | 56 | $1,179 |
| Acetazolamide | 25 | $970 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $806 |
| Ofloxacin | 68 | $761 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $538 |
| Brimonidine Tartrate | 20 | $373 |
| Latanoprost | 43 | $342 |
| Timolol Maleate | 13 | $107 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Sacramento
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.